Under the terms of the agreement, Reprocell can outsource part of the MCB manufacturing process at Texcell's GMP facility in France to establish GMP iPSC MCB. The agreement supplements a master service agreement the companies previously signed.

Cellular programming spurs next-generation cell therapies
Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success...

Advancing from CAR T-cell therapies to modified NK cell therapies
Chimeric antigen receptor (CAR) T-cell therapies have quickly become promising candidates for the treatment of many cancers. However, other immune cell...

New in vitro models offer effective way to study respiratory viruses
A new accessible and scalable protocol for manufacturing in vitro lung cell models could have applications in the development of new therapies for respiratory...

How one mammalian DNA polymerase challenges the central dogma of biology
New research demonstrates how an unusual mammalian DNA polymerase can facilitate the conversion of RNA into DNA -- the opposite of normal polymerase function....

Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...